These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15855019)

  • 1. PyNTTTTGT prototype oligonucleotide IMT504 is a potent adjuvant for the recombinant hepatitis B vaccine that enhances the Th1 response.
    Elias F; Flo J; Rodriguez JM; De Nichilo A; Lopez RA; Zorzopulos J; Nagle C; Lahoz M; Montaner A
    Vaccine; 2005 May; 23(27):3597-603. PubMed ID: 15855019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA vaccine.
    Zhao G; Jin H; Li J; Su B; Du X; Kang Y; Wang X; Wang B
    Viral Immunol; 2009 Apr; 22(2):131-8. PubMed ID: 19327000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high dose of IMT504, the PyNTTTTGT prototype immunostimulatory oligonucleotide, does not alter embryonic development in rats.
    Hernando-Insúa A; Rodriguez JM; Elías F; Fló J; López R; Franco R; Lago N; Zorzopulos J; Montaner AD
    Oligonucleotides; 2010 Feb; 20(1):33-6. PubMed ID: 19943802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
    Song ES; Park SA; Kim SH; Cho YJ; Ahn BY; Ahn BC; Lee NG
    FEMS Immunol Med Microbiol; 2007 Dec; 51(3):496-504. PubMed ID: 17877731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice.
    Qin W; Jiang J; Chen Q; Yang N; Wang Y; Wei X; Ou R
    Cell Mol Immunol; 2004 Apr; 1(2):148-52. PubMed ID: 16212903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg.
    Khajuria A; Gupta A; Malik F; Singh S; Singh J; Gupta BD; Suri KA; Suden P; Srinivas VK; Ella K; Qazi GN
    Vaccine; 2007 Jun; 25(23):4586-94. PubMed ID: 17498851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligonucleotide IMT504 induces an immunogenic phenotype and apoptosis in chronic lymphocytic leukemia cells.
    Rodriguez JM; Elias F; Montaner A; Flo J; Lopez RA; Zorzopulos J; Franco RJ; Lenial SP; Lopez Salón M; Pirpignani ML; Solimano J; Garay G; Riveros D; Fernandez J; Cacchione R; Dupont J
    Medicina (B Aires); 2006; 66(1):9-16. PubMed ID: 16555722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.
    Siegrist CA; Pihlgren M; Tougne C; Efler SM; Morris ML; AlAdhami MJ; Cameron DW; Cooper CL; Heathcote J; Davis HL; Lambert PH
    Vaccine; 2004 Dec; 23(5):615-22. PubMed ID: 15542181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymeric lamellar substrate particles as carrier adjuvant for recombinant hepatitis B surface antigen vaccine.
    Saini V; Sahoo MK; Murthy PK; Kohli D
    Vaccine; 2009 Apr; 27(17):2372-8. PubMed ID: 19428853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of immune responses to hepatitis B vaccine in immunodepressed mice by CpG oligodeoxynucleotide.
    Qin WB; Jiang JW; Yang N; Chen QE; Wang YF; Wei XC; Ou RQ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):647-50. PubMed ID: 15555425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA.
    Shen E; Li L; Li L; Feng L; Lu L; Yao Z; Lin H; Wu C
    Cell Mol Immunol; 2007 Apr; 4(2):113-20. PubMed ID: 17484805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant.
    Nesburn AB; Ramos TV; Zhu X; Asgarzadeh H; Nguyen V; BenMohamed L
    Vaccine; 2005 Jan; 23(7):873-83. PubMed ID: 15603887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
    Li X; Yang X; Li L; Liu H; Liu J
    Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination.
    Du X; Zheng G; Jin H; Kang Y; Wang J; Xiao C; Zhang S; Zhao L; Chen A; Wang B
    J Gene Med; 2007 Feb; 9(2):136-46. PubMed ID: 17310492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
    Joseph A; Louria-Hayon I; Plis-Finarov A; Zeira E; Zakay-Rones Z; Raz E; Hayashi T; Takabayashi K; Barenholz Y; Kedar E
    Vaccine; 2002 Sep; 20(27-28):3342-54. PubMed ID: 12213404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses.
    Trujillo-Vargas CM; Mayer KD; Bickert T; Palmetshofer A; Grunewald S; Ramirez-Pineda JR; Polte T; Hansen G; Wohlleben G; Erb KJ
    Clin Exp Allergy; 2005 Aug; 35(8):1003-13. PubMed ID: 16120081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different contribution of co-stimulatory molecules B7.1 and B7.2 to the immune response to recombinant modified vaccinia virus ankara vaccine expressing prM/E proteins of Japanese encephalitis virus and two hepatitis B virus vaccines.
    NAM JH; BANG HS; CHO HW; CHUNG YH
    Acta Virol; 2007; 51(2):125-30. PubMed ID: 17900219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years.
    Cooper CL; Angel JB; Seguin I; Davis HL; Cameron DW
    Clin Infect Dis; 2008 Apr; 46(8):1310-4. PubMed ID: 18444872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells.
    Bauer T; Günther M; Bienzle U; Neuhaus R; Jilg W
    Liver Transpl; 2007 Mar; 13(3):434-42. PubMed ID: 17318860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.